Further research to advance this novel senolytic strategy using CDK4/6i and GLS1i into clinical trials is anticipated, with a focus on targeting BrafV600E melanoma, inclusive of variants with acquired resistance to Braf and/or MEK inhibitors. Here, BRAF is linked to melanoma.